Press Room

Quanticate is pleased to partner with Antev Limited on a Phase II, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH antagonist, in Participants with Advanced Prostate Cancer.

Prostate cancer is one of the most commonly diagnosed cancers and is a major cause of death in men worldwide. GnRH antagonists act by direct inhibition of GnRH receptors and therefore Luteinizing Hormone to reduce testosterone levels.

Quanticate is a Data Specialist CRO who has extensive experience supporting numerous oncology programs, including in prostate cancer. We are very much looking forward to supporting Antev on this important and crucial study by providing specialist statistics, programming, data management and medical writing solutions.

Deepu Joseph, VP of Clinical Data Management, and Claude Price, Associate Director Clinical Data Management, will be attending the SCDM Annual Conference, 13th - 16th Sep, 2020.

Quanticate would like to congratulate GSK on their recent US FDA approval Rukobia (fostemsavir), a first in-class treatment for HIV in adults.  Until now patients had few treatment options available.  Quanticate provided statistical analysis and programming to support GSK on this important program.

Quanticate is pleased to announce that we have been certified as a "Great Place to Work" in India by the “Great Place to Work Institute” in the small and mid-size organizations category for the period from April 2020 – March 2021. This award reflects the positive culture, diverse workforce, commitment and motivation from our employees and the efforts from Quanticate to build a workplace that is a great place to learn and develop. It helps demonstrate our Coded to Care Mantra and continued commitment to supporting our people.

March 24, 2020:  Covid-19 Update

With the global spread of Covid-19, Quanticate have been focused in recent weeks on ensuring our staff and their families are safe and that we are able to continue delivering for our customers both now and in the future.

LONDON (UK) - Quanticate, a leading global data-focused contract research organization (CRO), has been included on the Pharma Times Fast 50 list for 2020.

LONDON (UK) - Quanticate, a leading global data-focused contract research organization (CRO), has been named the Best Contract Research Organization – Specialist Providers in the 2019 SCRIP Awards.

The Scrip Awards recognize the essential role that the pharmaceutical and biotechnology industry’s top achievers play in improving healthcare and drug development. The ‘Best Contract Research Organization - Specialist Providers’ category acknowledges the critical role that niche CROs play in drug development.

LONDON (UK) - Quanticate, a leading global data-focused clinical research organisation (CRO), has announced plans to expand its presence in North America with the opening of a new office in Toronto. The announcement comes as a result of continued success and a year of growth across it’s key strategic partnerships including expansion of work with a number of top five pharmaceutical companies.

LONDON (UK) - Quanticate, a leading global data-focused clinical research organisation (CRO), has appointed of Paula Finch as Senior Vice President of Project Delivery.

LONDON (UK) - Quanticate, a leading global data-focused clinical research organisation (CRO) has launched QVigilance to provide dedicated pharmacovigilance (PV) and risk management services.